Bortezomib For Injection

Bortezomib For Injection Specification

Brand Name
As per manufacturer

Packaging Type
Glass Vial

Life Span
24-36 months (Refer to expiry date on pack)

Pacakaging (Quantity Per Box)
1 vial per box

Origin of Medicine
India

Indication
Treatment of Multiple Myeloma and Mantle Cell Lymphoma

Dosage Form
Injection

Salt Composition
Bortezomib

Drug Type
Injection

Ingredients
Bortezomib

Physical Form
Liquid

Function

Recommended For
Multiple Myeloma and Mantle Cell Lymphoma

Dosage
As prescribed by physician

Dosage Guidelines
As Per suggetion

Suitable For
Adults

Quantity
1 vial per box

Storage Instructions
Cool & Dry Place

Side Effects
Nausea, fatigue, diarrhea, neuropathy

Reconstitution Medium
Sterile 0.9% Sodium Chloride Solution

Availability
Prescription Only

Route of Administration
Intravenous/subcutaneous

Strength
2 mg/vial

Contraindications
Known hypersensitivity to bortezomib, boron or mannitol

Molecular Formula
C19H25BN4O4

Molecular Weight
384.24 g/mol

Colour of Content
White to Off-White

Bortezomib For Injection Trade Information

Minimum Order Quantity
50 Pieces

Supply Ability
100 Pieces Per Day

Delivery Time
3-4 Days

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

About Bortezomib For Injection

Bortenat

Bortenat contains Bortezomib that belongs to a class of medicines known as antineoplastic agents. These medicines are also used for treating multiple myeloma and in curing mantle cell lymphoma. Moreover, this medicine reacts straightaway with certain proteins in the body to arrest the growth of cancer cells. This drug is supplied in 3.5 mg single use vial.

Specification
Brand Name	Bortenat
Content	Bortezomib
Manufacturer	Natco Pharma
Strength	3.5 Mg
Form	Injection
Pack	Bottle

Note: Bortenat is a prescription Drug and should be used under Proper Medical Guidance and Advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug.

Frequently Asked Questions

1. What is the purpose of bortezomib injection?

Ans - Multiple myeloma (blood plasma cell cancer) and mantle cell lymphoma are both conditions that are treated with the injection of bortezomib. It is antineoplastic to use bortezomib (cancer medicine). Cancer cells are hampered in their proliferation before being subsequently eliminated by the body.

2. Is bortezomib a cancer treatment?

Ans - By inhibiting some of the enzymes required for cell growth, the drug bortezomib may prevent the growth of cancerous cells. Lenalidomide is an example of a chemotherapy treatment that stops the growth of cancer cells in one of three ways: by killing the cells, by preventing their division, or by preventing their dissemination.

3. When does bortezomib start to work?

Ans - According to data from SUMMIT and APEX, the median duration to a first response is 1.3 months, indicating that most patients respond to treatment quickly (Richardson et al 2003, 2005a).

4. Does bortezomib result in baldness?

Ans - Velcade does not directly cause hair loss, but other medications taken alongside Velcade may cause it as a side effect. People who use Velcade along with the cytotoxic medication cyclophosphamide, for instance, may experience hair loss.

How Bortezomib For Injection Works

Bortezomib functions by inhibiting proteasomes in cancer cells, leading to their death. This targeted action helps in reducing abnormal cell growth associated with multiple myeloma and mantle cell lymphoma. Its mechanism provides an essential option for managing these specific cancer types, under careful medical supervision.

Guidelines for Reconstitution and Administration

To prepare Bortezomib For Injection, healthcare professionals reconstitute the powder with sterile 0.9% sodium chloride solution. The resulting liquid is suitable for intravenous or subcutaneous administration. It is crucial that this process is performed in a medical setting by trained personnel to ensure both effectiveness and safety.

Benefits and Storage

Bortezomib offers significant therapeutic benefit by slowing disease progression in multiple myeloma and mantle cell lymphoma. For optimal stability, store vials in a cool, dry place and never use beyond the expiry date on the packaging. One vial is intended for a single patient as prescribed.

FAQ's of Bortezomib For Injection:

Q: How is Bortezomib For Injection administered to patients?

A: Bortezomib For Injection is administered either intravenously or subcutaneously by qualified healthcare professionals after reconstitution with sterile 0.9% sodium chloride solution.

Q: What are the main uses of Bortezomib For Injection?

A: This medication is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma in adult patients.

Q: Who should not take Bortezomib For Injection?

A: Individuals with known hypersensitivity to bortezomib, boron, or mannitol should not use this injection.

Q: What potential side effects are associated with Bortezomib?

A: Common side effects include nausea, fatigue, diarrhea, and neuropathy. Inform your doctor if any symptoms are severe or persistent.

Q: When should Bortezomib For Injection be used?

A: This product should be used strictly as directed by a physician, as part of a prescribed chemotherapy regimen for eligible cancer patients.

Q: How should I store Bortezomib For Injection?

A: Store the vial in a cool, dry place in accordance with the storage instructions, and always check the expiry date before use.

Q: What is the benefit of using Bortezomib For Injection?

A: Bortezomib can help control and slow the progression of multiple myeloma and mantle cell lymphoma, improving patient outcomes as part of a comprehensive treatment plan.

Tell us about your requirement